Fei Ye, Xiao Yuan, Wanjun Yu, Yali Ma, Chaoming Mao, Xiaoqin Li, Jian Li, Chunhua Dai, Fenhong Qian, Junrong Li, Xiujuan Fan, Yuepeng Zhou, Dongfang Dai, Deqiang Wang, Deyu Chen, Sheng Xia, Minghui Zhang
Background: To evaluate the efficacy and safety of allogenic CD8 + natural killer T (CD8+ NKT) immunotherapy combined with gefitinib in the treatment of advanced or metastatic EGFR mutant non-small cell lung cancer (NSCLC). Methods: This study is prospective. The NSCLC patients with exon 19 (Ex19del) or exon 21 L858R point mutations, and response to gefitinib treatment were enrolled into the trial to be randomly assigned into the gefitinib arm and the gefitinib/NKT arm. Allogenic CD8+ NKT cells were cultured in vitro and adaptive transferred into the patients via vein in the gefitinib/NKT arm...
2024: Technology in Cancer Research & Treatment